PUBLISHER: The Business Research Company | PRODUCT CODE: 1271026
PUBLISHER: The Business Research Company | PRODUCT CODE: 1271026
“Anti-Cancer MAbS Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on anti-cancer mabs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for anti-cancer mabs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The anti-cancer mabs market global report ” from The Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Major players in the anti-cancer mabs market are Amgen Inc., Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Genmab AS, GlaxoSmithKline PLC., Johnson & Johnson, Novartis AG, Merck & Co. Inc., Spectrum Pharmaceuticals Inc., AstraZeneca plc., Pfizer Inc., Roche Holding AG, Gilead Sciences, Bayer HealthCare, and ImmunoGen Inc.
The global anti-cancer MAbS market is expected to grow from $56.27 billion in 2022 to $62.47 billion in 2023 at a compound annual growth rate (CAGR) of 11.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The anti-cancer MAbS market is expected to reach $91.12 billion in 2027 at a CAGR of 9.9%.
The anticancer mAbs market consists of sales of monoclonal antibody therapies such as avastin, Herceptin, keytruda, opdivo, darzalex, and perjeta. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
Anticancer monoclonal antibodies (mAbs) are the antibodies used for monoclonal antibody therapy to target and destroy cancer cells. These mAbs are intended to bind to specific proteins or chemicals located on the surface of cancer cells, preventing cancer growth and spread.
Noth America was the largest region in the anti-cancer MAbS market in 2022. Asia Paicific is expected to be the fastest-growing region in the forecast period. The regions covered in the anticancer mAbs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The main types of anti-cancer mabs are murine antibodies, chimeric antibodies, humanized antibodies and others. Murine refers to a type of monoclonal antibody (mAb)that are a laboratory-made copy of a single antibody, produced by a single B cell, derived from mice or rats, they are used to bind to a specific antigen. These are used in various applications such as blood cancer, breast cancer, lung cancer, melanoma, colorectal cancer, liver cancer and others and are used in hospitals, research institutes, and others.
The increasing prevalence of cancer across the globe is expected to propel the growth of the anticancer MABs market going forward. Cancer refers to the disease that is a chronic disease that lasts for a longer time. Anticancer monoclonal antibodies (mAbs) are specifically designed to bind specific proteins found on cancerous cells as well as they use genetically engineered versions of the immune system's own antibodies to target and destroy cancer cells, as a result, increasing the prevalence of cancer increases the demand for anticancer MABs market. For instance, in 2020, according to research by World Cancer Research Fund International, a UK-based not-for-profit association providing cancer prevention research, estimated 18.1 million active cancer cases globally along with 9.3 million cases in men and 8.8 million in women. Therefore, increasing the prevalence of cancer across the globe is propelling the growth of the anticancer mAbs market.
Product innovations are a key trend gaining popularity in the anticancer mAbs market. Major companies operating in the anticancer mAbs market are introducing more effective and targeted cancer treatments, such as mAbs drugs to strengthen their position in the market. For instance, in May 2022, Roche Holding AG, a Switzerland-based pharmaceutical company launched PHESGO. PHESGO (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is a unique monoclonal antibody (mAb) combination treatment for HER2-positive early breast cancer. It is a subcutaneous (under the skin) injection that combines the two mAbs pertuzumab and trastuzumab with the enzyme hyaluronidase. The addition of hyaluronidase, an enzyme that helps to increase the absorption of the mAbs, allows the treatment to be given subcutaneously rather than intravenously.
In May 2021, Exelixis Inc., a US-based genomics-based drug discovery company acquired GamaMabs Pharma SA for an amount of $5 million. With the acquisition of GamaMabs' AMHR2 antibody technology, Exelixis Inc. aims to add an existing drug product portfolio of GamaMabs and related manufacturing cell lines. GamaMabs Pharma SA is a France-based biotechnology focused on developing innovative monoclonal antibodies for the treatment of solid tumors.
The countries covered in the anticancer mAbs market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The anti-cancer MABs market research report is one of a series of new reports from The Business Research Company that provides anti-cancer MABs market statistics, including anti-cancer MABs industry global market size, regional shares, competitors with an anti-cancer MABs market share, detailed anti-cancer MABs market segments, market trends and opportunities, and any further data you may need to thrive in the anti-cancer MABs industry. This anti-cancer MABs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.